StreetAlpha
13F holdings · Q3 2026

Ikarian Capital

Dallas, TX · files as Ikarian Capital, LLC
Know the moment Ikarian Capital filesYou follow Ikarian Capital An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1778253

Ikarian Capital reported 125 stocks worth $504M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KOD (10.0%), ABVX (5.6%) and PCVX (4.5%). Compared with Q2 2026, the fund opened new positions in ORIC, DMRA and FRNM, added to PCVX, RCUS and CLDX, trimmed KOD, ABVX and ANIP and sold out of HIMS, RARE and BIOA.

Latest filing: what Ikarian Capital did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
19 new21 added31 trimmed20 sold outBought about $120M · sold about $172M
New 19
See all 19 →
Added 21
See all 21 →
Trimmed 31
See all 31 →
Sold out 20
See all 20 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$504M−17.5% vs last quarter · $994M including options
Stocks held12519 new · 20 sold out
Top 5 weight27.3%spread out
Turnover60%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
KOD
Kodiak Sciences Inc
$50.5M10.0%533K−527K (−50%)8 of 8
2
ABVX
Abivax SA
$28.4M5.6%286K−43K (−13%)5 of 8
3
PCVX
Vaxcyte Inc
$22.8M4.5%400K+12K (+3%)7 of 8
4
RCUS
Arcus Biosciences Inc
$19M3.8%735K+230K (+46%)5 of 8
5
CLDX
Celldex Therapeutics Inc
$16.8M3.3%519K+40K (+8%)3 of 8
6
AMLX
Amylyx Pharmaceuticals Inc
$16.3M3.2%561K+444K (+378%)3 of 8
7
PHVS
Pharvaris N V
$15.9M3.2%502K+194K (+63%)5 of 8
8
VERA
Vera Therapeutics Inc
$12.9M2.6%400K+90K (+29%)4 of 8
9
ANRO
Alto Neuroscience Inc
$12.3M2.4%482K+75K (+18%)8 of 8
10
COGT
Cogent Biosciences Inc
$11.9M2.4%370KNo change4 of 8
🔒 115 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
GALECTO INC
$8.7M336K
HIMS
Hims & Hers Health Inc
$6.5M188K
RARE
Ultragenyx Pharmaceutical in
$5.5M166K
BIOA
Bioage Labs Inc
$4.9M200K
BBIO
Bridgebio Pharma Inc
$4.3M57K

🔒 Free account: see all 20.

Options

valued at the underlying shares
StockTypeValueSharesChange
MRNA
Moderna Inc
Put$77M400K0
BMY
Bristol Myers Squibb Co
Put$61.9M993K+950,000
XBI
Spdr Series Trust
Put$47.3M300K0
PRAX
Praxis Precision Medicines I
Call$29.1M100K+79,800
IRON
Disc Medicine Inc
Put$25.5M389K+375,800

🔒 Free account: see all 20.

Reported value

last 8 quarters
$350MQ4 '24
$307MQ1 '25
$302MQ2 '25
$494MQ3 '25
$773MQ4 '25
$699MQ1 '26
$611MQ2 '26
$504MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Ikarian Capital 13F FAQ

What does Ikarian Capital own?

Ikarian Capital reported 125 stocks worth $504M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KOD (10.0%), ABVX (5.6%) and PCVX (4.5%). The table above lists every position in the filing (the top 10 without an account).

What did Ikarian Capital buy and sell in Q3 2026?

Compared with Q2 2026: 19 new positions, 21 added to, 31 trimmed and 20 sold out. New positions include ORIC, DMRA and FRNM. It sold all of HIMS, RARE and BIOA.

When will Ikarian Capital file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Ikarian Capital's portfolio worth?

The Q3 2026 filing reports $504M in US stocks ($994M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.